Immunotherapy, targeted treatments, HIPEC, and new delivery options ...

Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine ...

Trastuzumab deruxtecan is approved for HR-positive, HER2-low/ultralow metastatic breast cancer post-endocrine therapy, based on DESTINY-Breast06 trial results. The trial showed a 36% reduction in ...

Emerging immunotherapies and targeted therapies take aim at recently identified biomarkers ...

A regulatory decision is expected during the first quarter of 2026. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for ...

HERCESSI(TM) becomes one of two trastuzumab biosimilars on preferred formulary placement, expanding patient access to more affordable HER2-targeted oncology therapies RALEIGH, N.C., Jan. 5, 2026 ...

Please provide your email address to receive an email when new articles are posted on . Patients with HER2-positive metastatic breast cancer had a real-world PFS of 1 year on trastuzumab deruxtecan.

Trastuzumab emtansine (T-DM1) demonstrates sustained improvement in invasive disease-free survival and reduced the risk for death in human epidermal growth factor receptor 2 (HER2)-positive breast ...

Cardiotoxicity is an important adverse effect of trastuzumab in the treatment of breast cancer. Particularly in the adjuvant setting, a high risk of cardiotoxicity is unacceptable, since the ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved trastuzumab deruxtecan for a new breast cancer indication. The approval applies to patients ...

Patients treated with trastuzumab deruxtecan + pertuzumab had a statistically significant and clinically meaningful improvement in PFS compared with standard of care. Topline results were announced ...